Bio-Rad Laboratories, Inc. Forecasted to Post Q3 2025 Earnings of $3.00 Per Share (NYSE:BIO)

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Stock analysts at Zacks Research decreased their Q3 2025 EPS estimates for shares of Bio-Rad Laboratories in a note issued to investors on Tuesday, September 17th. Zacks Research analyst R. Department now expects that the medical research company will earn $3.00 per share for the quarter, down from their prior forecast of $3.06. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.31 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q1 2026 earnings at $3.31 EPS and Q2 2026 earnings at $2.82 EPS.

A number of other equities analysts also recently weighed in on BIO. StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Royal Bank of Canada reissued an “outperform” rating and issued a $401.00 price objective on shares of Bio-Rad Laboratories in a research report on Friday, August 16th. Jefferies Financial Group restated a “hold” rating and set a $315.00 target price (down previously from $440.00) on shares of Bio-Rad Laboratories in a research note on Monday, June 3rd. Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 price target on the stock. Finally, Citigroup lifted their target price on Bio-Rad Laboratories from $300.00 to $350.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, Bio-Rad Laboratories currently has an average rating of “Hold” and a consensus price target of $358.20.

Bio-Rad Laboratories Stock Performance

Shares of BIO stock opened at $344.60 on Friday. The company has a fifty day moving average price of $322.27 and a two-hundred day moving average price of $307.61. Bio-Rad Laboratories has a one year low of $261.59 and a one year high of $370.57. The stock has a market cap of $9.83 billion, a P/E ratio of -33.26 and a beta of 0.95. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.28 and a quick ratio of 4.63.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, August 1st. The medical research company reported $3.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.12 by $0.99. Bio-Rad Laboratories had a positive return on equity of 3.77% and a negative net margin of 51.73%. The company had revenue of $638.50 million for the quarter, compared to analysts’ expectations of $645.79 million. During the same quarter in the prior year, the business posted $3.00 EPS. The business’s revenue was down 6.3% compared to the same quarter last year.

Insider Transactions at Bio-Rad Laboratories

In related news, COO Andrew J. Last sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the sale, the chief operating officer now directly owns 7,559 shares of the company’s stock, valued at $2,494,016.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, COO Andrew J. Last sold 3,000 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the transaction, the chief operating officer now owns 7,559 shares of the company’s stock, valued at $2,494,016.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP James Barry sold 623 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the transaction, the executive vice president now owns 147 shares of the company’s stock, valued at $48,582.03. The disclosure for this sale can be found here. 17.06% of the stock is owned by insiders.

Hedge Funds Weigh In On Bio-Rad Laboratories

A number of institutional investors and hedge funds have recently bought and sold shares of BIO. Brio Consultants LLC acquired a new position in shares of Bio-Rad Laboratories in the fourth quarter valued at approximately $840,000. Principal Securities Inc. bought a new position in shares of Bio-Rad Laboratories during the fourth quarter valued at $41,000. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Bio-Rad Laboratories by 26.6% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 1,578 shares of the medical research company’s stock worth $510,000 after purchasing an additional 332 shares during the period. Norges Bank bought a new stake in shares of Bio-Rad Laboratories in the fourth quarter worth $73,142,000. Finally, BI Asset Management Fondsmaeglerselskab A S raised its position in Bio-Rad Laboratories by 70.8% during the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 779 shares of the medical research company’s stock worth $252,000 after purchasing an additional 323 shares during the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.